About this condition
Brain Cancer — Hereditary Risk
Approximately 5-10% of brain tumors have hereditary predisposition. Key syndromes include: neurofibromatosis type 1 (NF1 — optic pathway gliomas, malignant peripheral nerve sheath tumors), neurofibromatosis type 2 (NF2/LZTR1/SMARCB1 — bilateral vestibular schwannomas, meningiomas), Li-Fraumeni syndrome (TP53 — gliomas, choroid plexus carcinoma), von Hippel-Lindau (VHL — hemangioblastomas), tuberous sclerosis (TSC1/TSC2 — subependymal giant cell astrocytoma), and Gorlin syndrome (PTCH1 — medulloblastoma).
Targeted therapies are transforming hereditary brain tumor management. Selumetinib (MEK inhibitor) is FDA-approved for NF1-associated plexiform neurofibromas and shows activity against NF1 optic pathway gliomas. Bevacizumab produces tumor shrinkage and hearing improvement in NF2 vestibular schwannomas. Everolimus (mTOR inhibitor) is approved for TSC-associated subependymal giant cell astrocytomas. These gene-targeted therapies require molecular confirmation of the underlying syndrome.
Brain tumor predisposition syndrome recognition is critical in pediatrics — medulloblastoma in an infant should prompt Gorlin (PTCH1) and SUFU testing; choroid plexus carcinoma in a child is nearly pathognomonic for TP53/Li-Fraumeni; optic pathway glioma should prompt NF1 evaluation. Molecular diagnosis determines surveillance protocols, treatment selection, and family screening.
Selumetinib is FDA-approved for NF1 plexiform neurofibromas — the first gene-targeted therapy for neurofibromatosis. NF1 molecular confirmation is required for treatment eligibility.
- Gene locus
- NF1 (17q11.2), NF2 (22q12.2), TP53 (17p13.1), VHL (3p25.3), TSC1 (9q34.13), TSC2 (16p13.3), PTCH1 (9q22.32)
